Vaccination against pneumococcal disease: Current questions and future opportunities

BMC News and Views

Volumn 1, Issue 1, 2000, Pages

  Whitney, Cynthia G ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BACTERIUM ISOLATION; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; EDITORIAL; GOVERNMENT; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION PREVENTION; INFECTION RISK; LONG TERM CARE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; UGANDA; UNITED STATES; VACCINATION;

EID: 0001897089     PISSN: 14718219     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-8219-1-7     Document Type: Editorial

References (24)

1. National Center for Health Statistics: Health, United States, 2000 with adolescent health chart-book. Hyattsville, Maryland: Centers for Disease Control and Prevention 2000 176 177
2. Epidemiology of pneumococcal infections in the elderly. JC Butler A Schuchat, Drugs & Aging 1999 15 11 19 10690791
3. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. JP Nuorti JC Butler L Gelling JL Kool AL Reingold DJ Vugia, Ann Intern Med 2000 132 182 90 10651598
4. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. N French J Nakiyingi LM Carpenter, Lancet 2000 355 2106 2111 10902624
5. Life with the pneumococcus: notes from the bedside, laboratory, and library. R Austrian, Philadelphia: University of Pennsylvania Press 1985 59
6. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-8. GV Doern AB Brueggemann H Huynh E Wingert P Rhomberg, Emerg Infect Dis 1999 5 757 765 10603208
7. Emergence of drug-resistant pneumococcal infections in the United States. RF Breiman JC Butler FC Tenover JA Elliott RR Facklam, JAMA 1994 271 1831 1835 8196139
8. Centers for Disease Control and Prevention: Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 1997 46 1 24
9. U.S. Preventive Services Task Force: Guide to clinical preventive services. Baltimore: Williams & Wilkins 1996 803 804
10. American College of Preventive Medicine practice policy statement: Adult Immunizations. AR Fingar BJ Francis, Am J Prev Med 1998 14 156 158 9631168
11. American College of Physicians Task Force on Adult Immunization/ Infectious Diseases Society of America. Guide for adult immunization. Philadelphia: American College of Physicians 1994
12. National Guideline Clearinghouse. Agency for Healthcare Research and Quality 2000 http://www.guideline.gov
13. American Academy of Family Physicians: AAFP Reference Manual. Appendix D: AAFP recommendations for periodic health examination. Kansas City (MO): American Academy of Family Physicians 1999
14. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. RA Moore PJ Wiffen BA Lipsky, 2000 http://BioMedcentral. com/1471-2296/1/1
15. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. RF Breiman DW Keller M Phelan, Arch Intern Med 2000 160 2633 2638 10999977
16. Pneumococcal disease among HIV-infected persons: incidence, risk factors, and impact of vaccination. MS Dworkin JW Ward LM Carpenter, Clin Infect Dis 2000
17. Randomized trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-age and elderly people. Å Örtqvist J Hedlund LÅ Burman, Lancet 1998 351 399 403 9482293
18. The impact of vaccination strategy and methods of information on influenza and pneumococcal vaccination coverage in the elderly population. PO Honkanen T Keistinen K Sirkka-Liisa, Vaccine 1997 15 317 320 9139492
19. Polysaccharide pneumococcal vaccine efficacy: an evaluation of current recommendations. JC Butler RF Breiman JF Campbell HB Lipman CV Broome RR Facklam, JAMA 1993 270 1826 1831 8411526
20. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. ED Shapiro AT Berg R Austrian, N Engl J Med 1991 325 1453 1460 1944423
21. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JE Sisk AJ Moskowitz W Whang, JAMA 1997 278 1333 1339 9343464
22. Centers for Disease Control and Prevention: Prevention of pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices. Morb Mortal Wkly Rep 2000 49 (No. RR-9) 1 35
23. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: impact on pneumonia, otitis media, and an update on invasive disease - results of the Northern California Kaiser Permanente Efficacy Trial,. S Black H Shinefield P Ray, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA 1999
24. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: results of the Northern California Kaiser Permanente Efficacy Trial. S Black H Shinefield P Ray, Pediatr Infect Dis J 2000 19 187 95 10749457